Literature DB >> 20571936

Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.

Yun-feng Shan1, Yuan-lan Huang, Yuan-kang Xie, Yan-he Tan, Bi-Cheng Chen, Men-tao Zhou, Hong-qi Shi, Zheng-ping Yu, Qi-tong Song, Qi-yu Zhang.   

Abstract

Recently, two hepatic lineage markers epithelial cell adhesion molecule (EpCAM) and α-fetoprotein (AFP) were used to classify hepatocellular carcinoma (HCC) into four subtypes with prognostic implication. In the present study, we further evaluated the clinicopathologic and angiogenic characteristics among these HCC subtypes. EpCAM expression was investigated by immunohistochemistry in 115 HCC primary tumors. Based on EpCAM immunostaining and serum AFP levels, 115 HCC cases were classified into four subtypes: EpCAM+AFP+ (26.1%), EpCAM-AFP+ (20.0%), EpCAM+AFP- (20.8%), and EpCAM-AFP- (33.1%). EpCAM+AFP+ and EpCAM-AFP+ HCC were associated with late TNM stages and high frequencies of venous invasion, whereas EpCAM+AFP- and EpCAM-AFP- subtypes were associated with early TNM stages and low frequencies of venous invasion. Furthermore, EpCAM+AFP+ HCC had a significantly higher microvessel density (MVD) and higher level of VEGF (Vascular epithelial growth factor) expression than the other three subtypes. In conclusion, our study indicated that subtype classification of HCC based on EpCAM and AFP status had clinicopathologic and biologic implications in aggressive phenotype and angiogenesis. We also suggest that the EpCAM+AFP+ HCC patients might be potential therapeutic candidates for anti-angiogenesis therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571936     DOI: 10.1007/s12032-010-9600-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

1.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

2.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.

Authors:  X Zhang; J P Gaspard; D C Chung
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 3.  Genomics and signaling pathways in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Philippa Newell; Derek Y Chiang; Scott L Friedman; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2007-02       Impact factor: 6.115

Review 4.  Wnt signaling in angiogenesis.

Authors:  Nancy L Parmalee; Jan Kitajewski
Journal:  Curr Drug Targets       Date:  2008-07       Impact factor: 3.465

5.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

Authors:  Ju-Seog Lee; In-Sun Chu; Jeonghoon Heo; Diego F Calvisi; Zongtang Sun; Tania Roskams; Anne Durnez; Anthony J Demetris; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

6.  Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma.

Authors:  L Messerini; L Novelli; C E Comin
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 7.  An overview of small-molecule inhibitors of VEGFR signaling.

Authors:  S Percy Ivy; Jeannette Y Wick; Bennett M Kaufman
Journal:  Nat Rev Clin Oncol       Date:  2009-09-08       Impact factor: 66.675

8.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

9.  Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.

Authors:  Qing Zhang; Jun Zhou; Xiao-Ming Ku; Xin-Guo Chen; Li Zhang; Jing Xu; Guang-Sheng Chen; Qin Li; Feng Qian; Rong Tian; Ning Wen; Zhi-Nan Chen
Journal:  Eur J Cancer Prev       Date:  2007-06       Impact factor: 2.497

Review 10.  Wnt/Frizzled signaling in angiogenesis.

Authors:  Marielba Zerlin; Martin A Julius; Jan Kitajewski
Journal:  Angiogenesis       Date:  2008-02-06       Impact factor: 9.596

View more
  27 in total

1.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

Review 2.  Cancer stem cells: a systems biology view of their role in prognosis and therapy.

Authors:  Susan D Mertins
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

Review 3.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

4.  Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein.

Authors:  Edoardo G Giannini; Franco Trevisani
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

5.  Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?

Authors:  Yeo Jeong So; Sophia Frentzas; Eva Segelov
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

6.  Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma.

Authors:  Chih-Jan Ko; Chia-Jung Li; Meng-Yu Wu; Pei-Yi Chu
Journal:  Exp Ther Med       Date:  2018-09-26       Impact factor: 2.447

7.  The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.

Authors:  Feng Li; Huazong Zeng; Kejing Ying
Journal:  Med Oncol       Date:  2010-08-18       Impact factor: 3.064

8.  Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.

Authors:  Chia-Jui Yen; Masatoshi Kudo; Ho-Yeong Lim; Chih-Hung Hsu; Arndt Vogel; Giovanni Brandi; Rebecca Cheng; Ioana Simona Nitu; Paolo Abada; Yanzhi Hsu; Andrew X Zhu; Yoon-Koo Kang
Journal:  Liver Cancer       Date:  2020-05-05       Impact factor: 11.740

9.  TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Authors:  Shanglei Ning; Sen Guo; Jianjun Xie; Yunfei Xu; Xiaofei Lu; Yuxin Chen
Journal:  J Gastrointest Surg       Date:  2012-12-01       Impact factor: 3.452

10.  TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.

Authors:  Shanglei Ning; Nan Liang; Bin Liu; Xin Chen; Qi Pang; Tao Xin
Journal:  Neurol Sci       Date:  2013-02-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.